RGS19 and ovarian carcinoma: According to The Cancer Genetic Atlas (TCGA) and DepMap databases, RGS19 has been reported to be overexpressed in numerous cancers, particularly in bladder and ovarian cancers, where RGS19 can achieve unrestricted cell proliferation by enhancing AKT signalling and cell cycle control of the immune system.